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Introduction
The elderly often seek medical attention because of gas-
troduodenal diseases. It is well known that Helicobacter
pylori (H. pylori) infection is associated with several
gastroduodenal diseases1–3. This infection is usually
acquired before 10 years of age, but the prevalence of
H. pylori infection is higher in the elderly, probably
related to the poorer socioeconomic and sanitary con-
ditions in this age cohort4,5. Although the majority of
H. pylori-infected patients will remain asymptomatic
throughout life, about 10–15% patients will develop
peptic ulcer disease (PUD) and 1% will develop gastric
cancer or mucosa-associated lymphoid tissue lym-
phoma (MALToma)2,6–9. Notably, gastric cancer, the most
severe clinical outcome after H. pylori infection, usu-
ally occurs in the elderly1–3. The secretion of gastric acid
has been reported to decrease with age in H. pylori-
positive subjects, probably related to the higher preva-
lence of fundal atrophic gastritis in elderly patients10.
The secretion of protective prostaglandins and hy-
drophobicity in nonsteroidal anti-inflammatory drugs
(NSAID) users are also decreased in the elderly11,12. The
proportion of duodenal ulcer to gastric ulcer is also
higher in the younger population (7:1) than in the 
elderly population (1:1.7)11,13. The incidence of com-
plicated PUD, such as bleeding or perforation, is also
higher in elderly patients14. These results illustrate the
differences in H. pylori infections in geriatric and non-
geriatric populations. However, it has been reported that
only 40–56% of elderly patients who were hospitalized
for PUD were tested for H. pylori infection and that
eradication therapy was given to only 50–73% of
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infected patients15,16. Thus, we should pay more atten-
tion to the diagnosis and treatment of H. pylori infec-
tion in elderly patients. In this article, papers published
in English were searched in PubMed using the key
words “H. pylori”, “elderly”, “geriatrics”, “diagnosis”, and
“treatment”. The similarities and differences in the
diagnosis and treatment of H. pylori infection between
elderly and non-elderly patients will be discussed.
H. pylori-associated Gastroduodenal
Diseases in the Elderly with Gastritis
There are three major phenotypes of gastritis after pro-
longed H. pylori infection, including mild pangastritis,
corpus-predominant gastritis, and antrum-predominant
gastritis2. The different phenotypes of gastritis are also
associated with different clinical outcomes after H. pylori
infection2,17,18. While patients with corpus-predominant
gastritis usually have gastric atrophy and hypochlor-
hydria and increased risk of developing gastric cancer,
patients with antrum-predominant gastritis usually have
a higher secretion of gastric acid and an increased risk of
duodenal ulcer disease2,17,18. In contrast, patients with
mild pangastritis usually do not have clinically significant
diseases2,17,18. The different clinical outcomes are prob-
ably related to the interactions between bacterial viru-
lence and host genetics after prolonged infection and
inflammation2,3. However, these three phenotypes of
gastritis are not separate entities, as antrum-predomi-
nant gastritis may progress to corpus-predominant gas-
tritis or pangastritis with time. Notably, both atrophic
gastritis and intestinal metaplasia are strongly associ-
ated with H. pylori and not with age per se19. Advanc-
ing age has no influence on gastric acid secretion 
in H. pylori-negative subjects10. However, gastric acid
secretion decreases with age in H. pylori-positive sub-
jects10. The grades of atrophy and intestinal metapla-
sia are also significantly higher in H. pylori-positive
than in H. pylori-negative subjects20. It has been re-
ported that eradication of H. pylori infection in elderly
patients can lead to a significant decrease in gastritis
activity as compared with no change in histology in
patients with continuing infection21. Eradication of
H. pylori infection in elderly patients with advanced
atrophic gastritis may also lead to a significant im-
provement in the mean histologic scores of inflamma-
tion, atrophy and intestinal metaplasia, after a mean
follow-up of 2.5 years after eradication therapy22,23.
Altogether, evidence indicates that cure of H. pylori in-
fection may lead to improvement of gastritis in elderly
patients as it does in non-elderly adult patients.
Peptic Ulcer Disease
Peptic ulcer disease (PUD) is a common disease world-
wide with a lifetime prevalence of about 10%24. Most
PUDs are related to H. pylori infection and NSAID
use2,24. Previous studies have shown that H. pylori is
present in 90–100% of patients with duodenal ulcer
and in 60–90% of patients with gastric ulcer. It is asso-
ciated with at least a three- to fourfold increased risk
of PUDs25,26. In elderly patients, however, the propor-
tion of NSAID-related peptic ulcer is higher than in
non-elderly patients11,13. Several studies have reported
that the prevalence of H. pylori infection in elderly
patients with PUD ranges from 58% to 78%27,28. In a
study conducted in 520 elderly patients with PUD,
Pilotto et al. reported that 39% of patients with gastric
ulcers and 24% of patients with duodenal ulcers had
recent NSAID use (alone or in combination with 
H. pylori infection)29. Eradication of H. pylori infection
in adult patients with a peptic ulcer can dramatically
reduce the ulcer recurrence risk to 5–20% at 1 year30,31.
A recent meta-analysis also revealed that H. pylori
eradication therapy was superior to no treatment in
preventing duodenal ulcer recurrence (relative risk,
0.19) and gastric ulcer recurrence (relative risk, 0.31)32.
This benefit was also observed in elderly patients.
Pilotto et al. reported that eradication of H. pylori can
reduce the ulcer recurrence rate from 41.6% to 2.2%
among elderly patients with H. pylori-associated PUD33.
Symptom relief was also observed in over 85% of
patients after treatment of this infection34.
Whether eradication of H. pylori can prevent the
occurrence of peptic ulcers in aspirin/NSAID users is
also an important issue to be addressed in the elderly.
H. pylori infection and aspirin/NSAID use have been
reported to have synergistic effects in the develop-
ment of peptic ulcers and ulcer bleeding in a meta-
analysis35. Eradication of H. pylori was also shown to
reduce the incidence of peptic ulcers in patients re-
ceiving NSAIDs36. In the eradicated group, Vergara et al.
found that peptic ulcers occurred in 7.4% (34/459)
patients, as compared with 13.3% (64/480) in the non-
eradicated group36. Sub-analyses further showed that
the risk reduction was more significant (odds ratio, 0.26)
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in NSAID-naïve patients than in previously treated
patients36. However, a study performed in elderly pa-
tients showed that maintenance proton pump inhibitor
(PPI) therapy for preventing ulcers appeared to be more
effective than H. pylori eradication therapy37. In sum-
mary, H. pylori eradication may prevent peptic ulcers
in naïve users of NSAID, but eradication therapy alone
is not sufficient to prevent NSAID-related ulcer disease
completely in chronic NSAID users38. PPI maintenance
therapy is helpful in the prevention of ulcer recurrence
in chronic NSAID users who have already experienced
peptic ulcer and/or ulcer bleeding38.
Gastric Cancer
Gastric cancer is the second most common cause 
of cancer-related deaths worldwide1–3. Several nested
case control studies and meta-analyses have reported
a two- to sevenfold increased risk of gastric cancer 
in H. pylori-infected patients39–41. In animal models,
Watanabe et al. demonstrated that 37% of Mongolian
gerbils developed gastric cancer 62 weeks after oral
inoculation of H. pylori42. A prospective observational
study in Japan revealed that 2.9% of the H. pylori-
infected patients developed gastric cancer over 7.8
years, whereas none of the non-infected subjects de-
veloped gastric cancer43. An interventional study in
China has shown a 37% risk reduction after 7.5 years in
patients who received H. pylori eradication therapy44.
However, the timing of eradication should be as early
as possible before the development of premalignant
lesions (e.g., in atrophic gastritis, intestinal metaplasia,
and dysplasia) in which many types of molecular dam-
age have become irreversible44. This was supported 
by two recent animal model studies45,46. Lee and col-
leagues reported that although the severity of dysplasia
in H. pylori-infected transgenic mice overexpressing
amidated gastrin (INS-GAS mice) could be reduced after
H. pylori eradication at 8, 12 and 22 weeks postinfec-
tion (WPI), the development of gastric intraepithelial
neoplasia was completely prevented only in mice that
received H. pylori eradication at 8 WPI45. Romero-Gallo
et al. also found that eradication of H. pylori 8 WPI
resulted in attenuation, but not in complete preven-
tion of premalignant and malignant lesions, whereas
none of the Mongolian gerbils treated with antibiotics
at 4 WPI developed gastric cancer46. A recent cost-
effectiveness analysis also found that early H. pylori
eradication once in a lifetime at age 30 years seemed
more cost-effective than the surveillance strategy47.
Nevertheless, in a recent consensus meeting on gastric
cancer prevention48, most experts agreed that eradica-
tion of H. pylori to prevent gastric cancer should not
be precluded in the elderly. However, further studies
are warranted to support this viewpoint.
Non-ulcer Dyspepsia
The role of H. pylori in the pathogenesis of non-ulcer
dyspepsia (NUD) remains controversial. Although some
studies reported that H. pylori-infected patients were
more likely to have ulcer-like dyspepsia, other studies
failed to find such an association49–51. Randomized
controlled trials also met with conflicting results, prob-
ably related to the lack of a validated dyspepsia ques-
tionnaire in the outcome assessments, short follow-up
periods, and inadequate H. pylori eradication regi-
mens52,53. However, a recent meta-analysis reported
that there was a 10% relative risk reduction of NUD 
in an H. pylori eradication group as compared with
placebo, and the number needed to treat to cure one
case with NUD was 1454. It was concluded that H. pylori
eradication therapy has a small but statistically sig-
nificant effect in H. pylori-positive NUD54. In elderly
patients, Pilotto et al. reported an improvement of
dyspeptic symptoms in 70% of patients with chronic
gastritis 2 months after treatment55. Catalano et al. also
reported a significant reduction in symptoms after
eradication therapy in 126 patients with functional
dyspepsia56. However, it should be emphasized that
endoscopy should be used instead of the test-and-treat
strategy for elderly patients with dyspepsia, because
the prevalence of gastroesophageal malignancy was
higher in these patients57,58.
Gastroesophageal Reflux Disease
The inverse relationships between H. pylori infection
and gastroesophageal reflux disease (GERD) have been
reported in adult patients, but their associations remain
controversial38,59. A meta-analysis examining 20 case-
control studies evaluating the prevalence of H. pylori
in patients with GERD showed that patients with reflux
disease from the Far East, rather than those from
Western countries, had a lower prevalence of H. pylori
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infection59. Controversies also exist regarding whether
eradication of H. pylori is likely to aggravate the sever-
ity of preexisting GERD or increase the risk of new-
onset GERD38. In an elderly population, Pilotto et al.
reported that the clinical response to PPI therapy for
GERD was not influenced by eradication therapy60.
The result was in agreement with a pH study where
there was no significant change in the percentage of
total time of esophageal pH < 4 after eradication of
H. pylori61. Therefore, the decision of whether to erad-
icate H. pylori infection or not should not be influenced
by concerns about aggravation of GERD symptoms38.
On the other hand, it has been reported that long-term
acid suppression with a PPI or H2 receptor blockers
may affect the pattern and distribution of gastritis62.
This alteration may lead to the development of corpus-
dominant gastritis, the acceleration of loss of special-
ized glands, and progression of atrophic gastritis62.
Therefore, it is recommended that H. pylori testing and
treatment should be considered in patients receiving
long-term PPI use38.
Diagnosis of H. pylori in the Elderly
Diagnostic tests for H. pylori infection include invasive
tests that require endoscopy and noninvasive tests that
do not need endoscopy2,38. Invasive tests include his-
tologic examination, a rapid urease test, and cultures.
Noninvasive tests include serology, a 13C-urea breath
test (UBT), a stool antigen test (polyclonal or mono-
clonal antibody), and immunologic tests (laboratory-
and office-based tests and tests on saliva and urine)2,38.
Histologic examination provides an additional aid for
assessing the severity of gastritis and the presence of
malignancy or premalignant lesions. The rapid urease
test is less expensive than histology and the result can
be obtained within 1 hour. Cultures provide the chance
to perform an antibiotic susceptibility test, but they
are not available in many settings. A serology test is
inexpensive and widely available, but its diagnostic
accuracy is low (80–84%)2,38. It is helpful to assess 
H. pylori infection in patients with a bleeding ulcer
and conditions associated with low bacterial density
(extensive mucosal atrophy). The UBT is an accurate
(accuracy > 95%) and readily available noninvasive
test2,38. The sensitivity and specificity of the stool anti-
gen test is 91% and 93%, respectively, if the stool sam-
ple is stored at −20°C before testing63. However, the
sensitivity decreases to 69% if the specimen is stored 
at room temperature for 2–3 days63. After eradication
treatment, the UBT or stool antigen test should be em-
ployed for confirmation of eradication except in cases
that require repeated endoscopy, such as in patients
with a gastric ulcer2,38.
There are some specific characteristics for the diag-
nosis of H. pylori infection in elderly patients. Because
of the higher prevalence of gastroesophageal malig-
nancy in elderly patients with dyspepsia, endoscopy is
usually indicated in this population57,58. Therefore, the
H. pylori test can be done by histologic examination,
the rapid urease test or culture of biopsy specimens
taken during endoscopy. However, the rapid urease test
performed on antral biopsies has a lower sensitivity in
patients aged 60 years and older because of the higher
prevalence of atrophic gastritis in the elderly64. In such
conditions, a biopsy may be taken from both the
antrum and corpus to increase the detection rate11,13.
The sensitivity, specificity and diagnostic accuracy of
serology in a study of elderly patients were 74.4%, 59%,
and 67%, respectively65. The false-negative rate for the
stool antigen test is also high in hospitalized elderly
patients, probably related to the high frequency of
chronic constipation in these patients66. On the other
hand, the UBT was reported to have a significantly
higher sensitivity (94%), specificity (> 95%) and accuracy
(98%) than other tests in the elderly67. In a study com-
paring five diagnostic tests, the authors found that
almost one-third of H. pylori infections would have
been undetected if the UBT had not been used68. There-
fore, the UBT may provide the opportunity to detect 
H. pylori infection in elderly patients with atrophic gas-
tritis who have a negative rapid urease test or histology
for H. pylori.
After eradication treatment, it is recommended
that elderly patients with a diagnosis of gastric ulcer or
MALToma should be evaluated by endoscopy to con-
firm the healing of the underlying diseases11,13,38. How-
ever, elderly patients with mild or moderate gastritis
may be assessed by UBT alone. The stool antigen test
may be used if the UBT is not available.
Treatment of H. pylori Infection in 
the Elderly
Recommendations for H. pylori eradication in the
Maastricht Consensus Report include patients with PUD,
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MALToma, atrophic gastritis, post-gastric cancer resec-
tion, first-degree relatives of patients with gastric cancer,
naïve users of NSAIDs, patients receiving long-term
maintenance treatment with PPIs, and patients who
wish to be tested and treated for H. pylori38. The rec-
ommended first-line therapy regimens are dependent
on the prevalence of antibiotic resistance (Figure)38. 
In areas with clarithromycin resistance rates less than
15–20% and a metronidazole resistance rate less than
40%, triple therapy with PPI, clarithromycin and metroni-
dazole is recommended. In areas with clarithromycin
resistance rates less than 15–20% and a metronidazole
resistance rate greater than 40%, triple therapy with
PPI, clarithromycin and amoxicillin is recommended.
However, in areas with clarithromycin resistance rates
greater than 20%, quadruple therapy is recommended
as the first-line therapy. However, the eradication rate
of the recommended first-line therapy is decreasing,
probably related to increased antibiotic resistance rate.
Therefore, several alternative first-line therapies, in-
cluding sequential therapy, levofloxacin-based triple
therapy, susceptibility and pharmacogenomic-based
triple therapy, have been proposed38.
There are also some special considerations in the
treatment of H. pylori infection for elderly patients.
First, it should be clarified that the recommended reg-
imens are equally effective in elderly patients. As it
has been reported that the antibiotic resistance rate to
metronidazole and clarithromycin were comparable
among elderly and non-elderly patients69 and that most
of the clinical trials assessing the efficacy of eradication
therapy for H. pylori enrolled both elderly and non-
elderly patients, it is expected that the results would
be applicable to elderly patients. Several studies per-
formed in elderly patients have also demonstrated that
PPI-based triple therapy for 1 week is highly effective
in geriatric patients11,13. Moshkowitz et al. reported that
the eradication rate of a combination of omeprazole,
clarithromycin and tinidazole was 92.9%70. Pilotto et al.
also reported that the eradication rate of lansoprazole
plus two of clarithromycin or metronidazole or amox-
icillin were 80–86% in the intention-to-treat (ITT)
group55. Dore et al. reported that the eradication rate
of quadruple therapy including esomeprazole 20 mg,
tetracycline 500mg, metronidazole 500 mg and bismuth
subcitrate tablets 240 mg twice daily for 10 days was
91% in ITT analysis71. Zullo et al. reported that 10-day
sequential therapy (rabeprazole 20 mg twice daily plus
amoxicillin 1g twice daily for the first 5 days, followed by
rabeprazole 20 mg, clarithromycin 500 mg and tinida-
zole 500 mg, all twice daily, for the remaining 5 days)
had a significantly higher eradication rate (94%) than
the standard 7-day triple therapy regimen (rabeprazole
20 mg, clarithromycin 500 mg and amoxicillin 1 g, all
twice daily) (80%) in elderly patients with peptic ulcer72.
Both regimens had similar high compliance rates (>95%)
and low adverse effect rates (< 12%)72. Therefore, the
recommended treatment strategy in the Maastricht
Consensus Report is applicable to elderly patients.
Second, we need to look at whether the dosage 
or eradication regimens should be adjusted in elderly
patients to reduce adverse effects and increase com-
pliance in the elderly. It has been reported that age
influences the disposition of clarithromycin and lanso-
prazole73. In contrast, the pharmacokinetics of amoxi-
cillin is influenced by the age-dependent decline in
renal function rather than by age per se73. Therefore,
several studies have evaluated the effect of dosage of
clarithromycin and PPIs on the eradication rate in the
elderly74–76. Pilotto et al. compared the curative rate of
low (250 mg twice daily) vs. high (500 mg twice daily)
doses of clarithromycin in combination with amoxi-
cillin and pantoprazole in elderly patients74. They found
that the curative rates of H. pylori infection in the low-
dose and high-dose groups were 83% and 79%, respec-
tively, in the ITT analysis (p>0.05)74. The adverse events
were also not significantly different between the two
groups, with 5% in the low-dose group and 9% in the
high-dose group74. The effect of PPI dosage on the
eradication rate in the elderly is also of importance.
Pilotto et al. reported that the eradication rate of low-
dose (20 mg daily) and high-dose (40 mg daily) omepra-
zole plus clarithromycin and metronidazole were
83.3% and 85.5%, respectively21. The eradication rates
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Figure. Treatment strategies according to antibiotic 
resistance38.
of low-dosage pantoprazole (40 mg once daily) in com-
bination with two of amoxicillin or metronidazole or
clarithromycin were greater than 80%75. Similarly, the
eradication rates of low-dosage rabeprazole-based triple
therapy (20 mg once daily) were also reported to be as
high as 88.5%76. These data suggest that low doses of PPI
and low doses of clarithromycin may be sufficient to
achieve an adequate eradication rate in elderly patients.
However, more studies in different ethnic groups are
warranted before a recommendation can be made.
Conclusion
The similarities and differences of H. pylori infection
in elderly and non-elderly patients are summarized in
the Table. The prevalence of H. pylori infection in-
creases with age worldwide. However, the prevalence
of H. pylori infection in patients with a peptic ulcer is
lower in elderly than in non-elderly patients, probably
related to the higher prevalence of NSAID-related PUD
in the elderly. Elderly patients with a peptic ulcer may
gain a similar benefit from cure of an H. pylori infec-
tion as non-elderly patients in terms of improvement
in symptoms and reduction in ulcer recurrence. Eradi-
cation of H. pylori infection may also lead to improve-
ment in histologic grading of chronic gastritis, but the
risk for gastric cancer cannot be completely prevented,
especially in patients with existing premalignant lesions.
The test-and-treatment strategy is not recommended
for elderly patients with uninvestigated dyspepsia
because of the higher incidence of gastroesophageal
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Table. Summary of similarities and differences of H. pylori infection and gastroduodenal disease between elderly and 
non-elderly adults
Elderly Non-elderly References
Prevalence of H. pylori Higher Lower 4, 5
Incidence of gastric cancer Higher Lower 1–3
Prevalence of complicated PUD Higher Lower 14
Proportion of NSAID related peptic ulcer Higher Lower 11, 13, 29
Secretion of protective prostaglandins Lower Higher 11, 12
and hydrophobicity in NSAID users
Gastric acid secretion
H. pylori un-infected Not affected by age 10
H. pylori infected Decrease with increasing age 10
GU:DU 1.7:1 1:7
Investigation for dyspepsia Endoscopy usually Test and treat in younger 57, 58
required patients without alarm 
symptoms
Biopsy site for H. pylori test From both antrum Antrum 11, 13
and body to increase 
detection rate 
Histologic change after eradication of Improvement in gastritis grading 21–23
H. pylori
Prevention of gastric cancer after Risk reduced, but not Risk markedly reduced, 44
eradication therapy completely prevented especially in the absence 
of premalignant lesions
Eradication rate of triple therapy Lower dosage of PPI and Standard dose is 74–76
clarithromycin may have recommended
equal eradication rate to
standard dose regimens
PUD = peptic ulcer disease; NSAID = nonsteroidal anti-inflammatory drugs; GU = gastric ulcer; DU = duodenal ulcer; PPI = proton pump inhibitor.
malignancy. However, the rapid urease test and his-
tology from the antrum may have lower sensitivity in
elderly patients, especially in those with atrophic gas-
tritis. It is recommended that the biopsy sites should
include both the antrum and corpus to increase the
detection rate. A UBT may be used in elderly patients
with atrophic gastritis if the rapid urease test or histol-
ogy fails to detect H. pylori infection. The treatment
strategy recommended in the Maastricht Consensus
Report is also applicable to elderly patients. Low doses
of a PPI and clarithromycin may be sufficient to achieve
an adequate eradication rate in elderly patients, but
more data are needed before a recommendation can
be made.
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